| abstract |
The present disclosure relates to a compound of formula (I) as an mPGES-1 inhibitor and a pharmaceutically acceptable salt thereof. These compounds are inhibitors of the microsomal prostaglandin E synthetase-1 (mPGES-1) enzyme and are therefore suitable for the treatment of pain and/or inflammation caused by a variety of diseases or conditions, such as Asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases. □ |